These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165 [TBL] [Abstract][Full Text] [Related]
4. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X. Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217 [TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801 [TBL] [Abstract][Full Text] [Related]
6. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Barg AA; Livnat T; Budnik I; Avishai E; Brutman-Barazani T; Tamarin I; Bashari D; Misgav M; Kenet G Br J Haematol; 2020 Oct; 191(2):282-290. PubMed ID: 32656767 [TBL] [Abstract][Full Text] [Related]
7. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809 [TBL] [Abstract][Full Text] [Related]
8. Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab. Garcia J; Zia A Pediatr Blood Cancer; 2021 May; 68(5):e28942. PubMed ID: 33559300 [TBL] [Abstract][Full Text] [Related]
9. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389 [TBL] [Abstract][Full Text] [Related]
10. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272 [TBL] [Abstract][Full Text] [Related]
11. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. Mahlangu JN BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367 [TBL] [Abstract][Full Text] [Related]
12. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146 [TBL] [Abstract][Full Text] [Related]
13. Emicizumab for hemophilia A without inhibitors. Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012 [No Abstract] [Full Text] [Related]
14. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro. Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693 [TBL] [Abstract][Full Text] [Related]
15. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963 [TBL] [Abstract][Full Text] [Related]
17. Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single-center retrospective study. Cohen CT; Diaz R Pediatr Blood Cancer; 2021 Nov; 68(11):e29325. PubMed ID: 34490988 [TBL] [Abstract][Full Text] [Related]
18. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Ebbert PT; Xavier F; Seaman CD; Ragni MV Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522 [TBL] [Abstract][Full Text] [Related]
19. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A. Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lebert D; Delavenne X; Dargaud Y J Thromb Haemost; 2024 Jul; 22(7):1857-1866. PubMed ID: 38583717 [TBL] [Abstract][Full Text] [Related]